Adlai Nortye Strikes Global Clinical Collaboration with Lilly and Merck for AN4035 Combination Trial
Adlai Nortye (ANL) has partnered with Lilly and Merck KGaA for a global Phase I trial of AN4035, a CEACAM5-targeting ADC. Lilly and Merck will supply cetuximab for free. ANL's stock has a Buy rating with a $31 target, but Spark rates it Neutral due to financial risks and bearish trends. ANL focuses on precision oncology, targeting RAS-addicted cancers.
How this was made
The 30-second read
Why it matters
The new supply agreements with Lilly and Merck reduce trial costs and add validation, potentially improving the company's valuation outlook.
Market read
First‑time disclosure of a multi‑partner clinical collaboration for ANL's lead ADC, a material catalyst for the micro‑cap biotech.
What to watch
No disclosed financial terms; the partnership could be more about data generation than immediate revenue.
Background
Adlai Nortye (ANL) is a clinical‑stage biotech focused on CEACAM5‑targeted ADCs and RAS pathway inhibitors.
Ticker impact
Adlai Nortye announced new clinical‑trial collaboration and supply agreements with Eli Lilly and Merck for its AN4035 ADC program.
possible modest upside as investors price in the added validation from major pharma partners
The deal is a fresh, material development for a micro‑cap biotech, but no immediate financial impact or price target change is disclosed.
Market effects
Adds credibility to the ADC and RAS‑targeted oncology sector, may encourage peer interest.
Limited to U.S., Australian and Chinese oncology trial markets.
Modest; primarily relevant to biotech investors.
Counterpoint
The collaboration may not translate into commercial success; trial risks remain high for early‑stage ADCs.
Key entities
- pharma partnerEli Lilly and Company
Provides cetuximab at no cost for U.S. trial sites.
- pharma partnerMerck KGaA
Supplies cetuximab for Australian and Chinese trial sites.
